Results 91 to 100 of about 19,757 (238)

Testosterone Versus Clomiphene Treatment of Hypogonadism: A Retrospective Analysis in US Veterans

Andrology, EarlyView.
ABSTRACT Background Male hypogonadotropic hypogonadism is a complex condition with a multifactorial etiology. Although testosterone replacement therapy (TRT) is the only approved treatment for male hypogonadism, clomiphene citrate (CC) is often used as an off‐label treatment.
Shourya Tadisina, Elizabeth Cristiano, Thomas Wiegmann, Ken Grasing, Betty Drees, Ram Sharma, Mariana Garcia‐Touza   +6 more
wiley   +1 more source

Four whole-istic aspects of schistosome granuloma biology: fractal arrangement, internal regulation, autopoietic component and closure

Memorias do Instituto Oswaldo Cruz, 2006
This paper centers on some whole-istic organizational and functional aspects of hepatic Schistosoma mansoni granuloma, which is an extremely complex system.
HL Lenzi, W de S Romanha, RM Zorzenon dos Santos, A Rosas, EM Mota, PPA Manso, LFG Caputo, M Pelajo-Machado   +7 more
doaj   +1 more source

Potential role of estradiol in ovariectomy-induced derangement of renal endocrine functions

Renal Failure, 2019
Menopause is an important physiological event associated with structural and functional changes in the kidneys. An animal model of bilateral ovariectomy was used to study the effects of estrogen depletion, replacement and antiestrogen on renal structure ...
Ahmed A. El-Gendy, Wael M. Elsaed, Hesham I. Abdallah   +2 more
doaj   +1 more source

Real‐world treatment patterns and outcomes in accelerated and blast‐phase myeloproliferative neoplasms: Insights from a large multi‐centre cohort analysis in the United Kingdom

British Journal of Haematology, EarlyView.
Summary This UK‐based retrospective analysis describes real‐world treatment patterns and outcomes in 175 patients with accelerated (AP, n = 69) or blast‐phase (BP, n = 106) ‘Philadelphia‐negative’ myeloproliferative neoplasms (MPN‐AP/BP) diagnosed between 2013 and 2025. Median age at transformation was 71 years.
Alexandros Rampotas, Gabriel Naylor‐Layland, Clare Brown, Ahmad Alabdulkarim, Jennifer Ryan, Frances Wadelin, Samah Alimam, Phyo Wint Wint Tun, Jonathan Lambert, Jennifer O'Sullivan, Andrew J. Wilson, Laith Tafesh, Andrew McGregor, Simone Claudiani, Andrew Innes, Emily Booth, James Leveson, Steve Knapper, Mamta Garg, Mani Dubey, Theodora Vatopoulou, Charlotte Brierley, Wai Ka Natalie Leung, Graham Greenfield, Mary Frances McMullin, Alesia Khan, Kate Milne, Duncan Brian, Anna Godfrey, Claire N. Harrison, Bethan Psaila, Patrick Harrington, Amy Kirkwood, Tim C. P. Somervaille, Donal P. McLornan, on behalf of the UK Blood Cancer Research Network MPN Clinical Study Group   +35 more
wiley   +1 more source

Renal‐vascular axis: unmasking its role in vascular endothelial growth factor‐inhibitor vascular toxicity in cancer patients

British Journal of Pharmacology, EarlyView.
Abstract Vascular toxicity is a growing concern in cancer patients receiving vascular endothelial growth factor inhibitor (VEGFi) therapy, posing a significant threat to patient prognosis. While the primary mechanism of VEGFi‐induced vascular toxicity is linked to redox‐sensitive reactions that disrupt vascular tone, leading to hypertension and ...
Grace Whelan, Karla B. Neves
wiley   +1 more source

Cancer pain: current practice and emerging targets

British Journal of Pharmacology, EarlyView.
Cancer pain (CP) arises from a complex interplay between the tumour and its microenvironment. Many patients experience a mixed pain phenotype that encompasses nociceptive, neuropathic and neuroinflammatory mechanisms, and vary across tumour type and disease stage. Despite decades of intensive research, the mainstay of cancer pain treatment is still non‐
Yi Ye, Marcin Chwistek, Zhiting Gong, Vanessa Uzonwanne, Xiaojie Shi, Arpad Szallasi   +5 more
wiley   +1 more source

Development of a specific anti-human EphA3 monoclonal antibody, Ea3Mab-20, for flow cytometry

Biochemistry and Biophysics Reports
Erythropoietin-producing hepatocellular (Eph) receptor A3 (EphA3) is a member of the Eph receptor family, which binds to its respective ligands, ephrins. These interactions are essential for normal development and tissue homeostasis.
Hiroyuki Satofuka, Hiroyuki Suzuki, Miu Hirose, Keisuke Shinoda, Takuya Nakamura, Tomohiro Tanaka, Mika K. Kaneko, Yukinari Kato   +7 more
doaj   +1 more source

Differential diagnosis of anemia in true and functional iron deficiency in patients with chronic diseases (malignant tumors) [PDF]

Терапевтический архив, 2016
Aim. To make a differential diagnosis of true and functional iron deficiency (ID) in anemia of chronic diseases (ACD). Subjects and methods. A total of 540 patients (785 investigations) and 311 healthy individuals (a control group) were examined.
G N Zubrikhina, V N Blindar, I I Matveeva   +2 more
doaj  

Physiological Basis of Sex Differences in Human Performance and Exercise‐Associated Pathology

Clinical Endocrinology, EarlyView.
ABSTRACT The presence of sex differences in human physical performance is well‐established and shaped by distinct endocrine, anatomical and physiological mechanisms. Despite sustained advances, our understanding of how inherent biological factors drive variations in exercise capacity and related pathologies is still developing.
David A. Holdsworth, Thomas J. O'Leary, Craig L. Doig, Natalie Taylor, Jasminder Dosanjh, David R. Woods, Michael J. Stacey, Robert M. Gifford   +7 more
wiley   +1 more source

Mechanisms of Thrombocytosis in Iron‐Deficiency Anemia

European Journal of Haematology, EarlyView.
ABSTRACT Iron‐deficiency anemia is frequently accompanied by reactive thrombocytosis, yet the mechanisms underlying this association remain incompletely understood. Beyond impaired erythropoiesis, iron availability has emerged as an active regulator of hematopoietic lineage decisions.
João Vitor Facco, Diane S. Krause, Sara T. Olalla Saad   +2 more
wiley   +1 more source